



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 31/44</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 95/05822</b> <b>(43) International Publication Date:</b> 2 March 1995 (02.03.95)
<b>(21) International Application Number:</b> PCT/EP94/02697 <b>(22) International Filing Date:</b> 10 August 1994 (10.08.94)  <b>(30) Priority Data:</b> 9317773.1                      26 August 1993 (26.08.93)                      GB  <b>(71) Applicant (for GB only):</b> PFIZER LIMITED [GB/GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).  <b>(71) Applicant (for all designated States except GB JP US):</b> PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. [BE/IE]; Alexandra House, Earlsfort Centre, Earlsfort Terrace, Dublin (IE).  <b>(71) Applicant (for JP only):</b> PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> CHAHWALA, Suresh, Babubhai [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). WINSLOW, Derek, Paul [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).		<b>(74) Agents:</b> BRADBROOK, Geoffrey, William et al.; Pfizer Limited, European Patent Dept., Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).  <b>(81) Designated States:</b> AU, CA, CN, FI, JP, KR, NO, NZ, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> INHIBITION OF SMOOTH MUSCLE CELL MIGRATION BY (R)-AMLODIPINE  <b>(57) Abstract</b> <p>The R(+) isomer of amlodipine is a potent inhibitor of smooth muscle cell migration despite its lack of calcium channel-blocking activity. It is useful for treating atherosclerosis, re-stenosis after angioplasty and endometriosis.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## INHIBITION OF SMOOTH MUSCLE CELL MIGRATION BY (R)-AMLODIPINE

This invention relates to treatment of medical conditions involving smooth muscle cell migration using the R(+) isomer of 3-ethyl-5-methyl-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methylpyridine-3,5-dicarboxylate, a compound having the approved non-proprietary name "amlodipine".

Amlodipine is a known calcium channel-blocking agent having vasodilatory activity and is currently used, generally in the form of a pharmaceutically acceptable salt such as its maleate or bezylate, in treatment of hypertension and angina. The compound and its preparation are described in European patent 0089167 B1. Amlodipine is a racemic compound due to its symmetry at position 4 of the dihydropyridine ring and the R- and S-enantiomers may be prepared by methods described in J. Med. Chem. 1986 29 1696 (Arrowsmith et al.) and European Patent Application 0331315 A. It was formerly believed that the two resolved enantiomers consisted of the R-(-) and S-(+) isomers but it has subsequently been found that these are in fact the S(-) and the R(+) isomer, respectively (see J. Med. Chem., 35, 3341-3344 (1992), Goldmann et al.). It is known that the calcium channel blocking activity of amlodipine is substantially confined to the S(-) form and the racemic mixture of R(+) and S(-) forms; the R(+) isomer has little or no calcium channel blocking activity and so is not likely to have significant cardiovascular effects when administered to a patient.

-2-

It is known that calcium channel blockers in general tend to inhibit smooth muscle cell migration. Thus they have been found to impede lesion development in various animal models of atherosclerosis (see Arteriosclerosis 5; 250 (1985), Willis et al., Arteriosclerosis 6; 237 (1986), Sugano et al.); also smooth muscle cell proliferative lesions following endothelial cell damage by balloon angioplasty are reduced by Isradipine, a calcium channel blocker (see Am. J. Pathol 124, 88-93 (1986) Handley et al.). During restenosis following balloon angioplasty and atherogenesis, vascular smooth muscle cells migrate from the media to the intima where they proliferate. It is believed that the efficacy of calcium channel blockers in animal models of re-stenosis post-balloon angioplasty and atherosclerosis is due to inhibition of vascular smooth muscle cell migration and subsequent reduction in smooth muscle cell proliferation and neointimal formation.

Thus, calcium channel blockers would be expected to be useful in the treatment of conditions of smooth muscle cell migration, including atherosclerosis, re-stenosis after angioplasty and endometriosis.

It has now been discovered, surprisingly and contrary to all existing theory, that the R(+) isomer of amlodipine, despite its lack of calcium channel-blocking activity, is a potent inhibitor of smooth muscle cell migration and its potency in this respect is greater than that of the S(-) isomer of amlodipine and some other known calcium channel-blockers. The R(+) isomer thus provides

-3-

a means of treating conditions involving smooth muscle cell migration without any concomitant cardiovascular effects.

It is therefore applicable to patients for whom reduction of blood pressure would be undesirable.

Thus, one aspect of the invention comprises the R(+) isomer of amlodipine or a pharmaceutically acceptable salt thereof for use in the treatment of conditions requiring inhibition of vascular smooth muscle cell migration.

The invention also provides use of the R(+) isomer of amlodipine or a pharmaceutically acceptable salt thereof for making a medicament for treatment of conditions requiring inhibition of smooth muscle cell migration.

A further aspect of the invention provides a pharmaceutical composition comprising the R(+) isomer of amlodipine or a pharmaceutically salt thereof and a pharmaceutically acceptable carrier or diluent, said composition being substantially free of calcium channel-blocking activity.

The invention also provides a method of treating conditions requiring inhibition of smooth muscle cell migration which comprises administering to the patient an effective amount of the R(+) isomer of amlodipine or a pharmaceutically acceptable salt thereof.

The pharmaceutically acceptable salts of amlodipine include the maleate and the bezylate. The conditions to

-4-

be treated include atherosclerosis, incipient re-stenosis following angioplasty, and endometriosis. The R(+) isomer of amlodipine may be used in the absence of the S(-) isomer and of any other compound acting as a calcium channel-blocker.

The effect of the R(+) isomer of amlodipine on smooth muscle cell migration was demonstrated using an aortic explant assay method in which the modulation, migration and proliferation of smooth muscle cells are assessed using primary cultures of rabbit aortic smooth muscle cells as described in Atherosclerosis 86 227-237 (1191). In this method uniform pieces of intimal/medial tissue from rabbit aorta were cultured in individual wells of a well plate. Migration was induced by addition of platelet-derived growth factor to the culture. Following a lag phase of several days the smooth muscle cells migrated from the explanted tissue and proliferated.

The distance covered by the outgrowing smooth muscle cells was measured.

This assay was carried out with varying concentrations of test compound added to the culture. The compounds thus tested were the maleate salts of the racemic mixture of R(+) and S(-) amlodipine, the maleate salts of R(+) and S(-) amlodipine separately and the known calcium channel-blocking agents nitrendipine and verapamil.

-5-

The results obtained are shown in Table 1, in which the percentage inhibition of smooth muscle cell migration for concentrations of test compound of 1 nanomole and 0.1 nanomole are recorded.

The racemic, R(+) and S(-) forms of amlodipine maleate were also tested for inhibition of K<sup>+</sup>-induced rat aortic contraction by the method described by Burges et al, J. Cardiovasc Pharmacol 9(1) 110-9; The 1C<sub>50</sub> (50% inhibitory concentration) values in nanomoles are also recorded in Table 1 and afford a measure of calcium channel-blocking activity.

**TABLE 1**

Compound	% inhibition of SMC migration from explants		inhibition of K <sup>+</sup> induced rat aortic contraction
	1nM	0.1nM	1C <sup>50</sup> (nM)
Amlodipine (racemate)	33	39	2
Amlodipine R(+)	39	36	1000
Amlodipine S(-)	30	21	1
Nitrendipine	28	14	
Verapamil	22	13	

It is evident from these results that the R(+) enantiomer of amlodipine is effective in inhibiting smooth muscle cell migration even though its activity as a calcium channel blocker is negligible.

For administration to man in the curative or

-6-

prophylactic treatment of conditions involving smooth muscle migration, oral doses of R(+) amlodipine or its salts may be in the range of 2-10 mg daily for an average adult patient (weighing 70 kg), that is a range similar to that used for amlodipine in the treatment of hypertension. However, the absence of cardiovascular effects allows administration of much larger doses than would be recommended for the calcium channel-blocking S(-) isomer or the racemate, with a correspondingly greater effect on cell migration. The oral dose of R(+) amlodipine or a salt thereof for the average adult patient may thus be 20mg or more and up to 100mg/day, or even greater. The actual dose used will be determined by a physician considering the age, weight, condition and medical history of the patient. For a typical adult patient individual tablets or capsules are likely to contain 1 to 100mg of active compound, in a suitable pharmaceutical vehicle or carrier. Dosages for intravenous administration would be in the range of 1-20mg of active compound per single dose as required. Thus, according to another aspect of the invention, there is provided a unit dose of a pharmaceutical composition substantially free of calcium channel-blocking activity containing (for oral administration) from 1mg to 100mg, preferably 20 to 100mg, of the R(+) isomer of amlodipine or a pharmaceutically acceptable salt thereof. A further aspect of the invention provides such a unit dose for intravenous administration containing from 1 to 20mg of the R(+) isomer of amlodipine or salt thereof.



### Claims

1. The R(+) isomer of amlodipine or a pharmaceutically acceptable salt thereof for use in the treatment of conditions requiring inhibition of vascular smooth muscle cell migration.
2. Use of the R(+) isomer of amlodipine or a pharmaceutically acceptable salt thereof for making a medicament for treatment of conditions requiring inhibition of smooth muscle cell migration.
3. A method of treating conditions requiring inhibition of smooth muscle cell migration which comprises administering to the patient an effective amount of the R(+) isomer of amlodipine or a pharmaceutically acceptable salt thereof.
4. A pharmaceutical composition comprising the R(+) isomer of amlodipine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said composition being substantially free of calcium channel-blocking activity.
5. A unit dose of a composition according to claim 4, for oral administration, containing from 1mg to 100mg of the R(+) isomer of amlodipine or a pharmaceutically acceptable salt thereof.
6. A unit dose according to claim 5, containing at least 20mg of the R(+) isomer of amlodipine or a pharmaceutically acceptable salt thereof.
7. A unit dose of a composition according to claim 4 for intravenous administration, containing from 1mg to 20mg of the R(+) isomer of amlodipine or a pharmaceutically salt thereof.

**A. CLASSIFICATION OF SUBJECT MATTER**  
**IPC 6 A61K31/44**

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

**IPC 6 A61K**

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	J. CARDIOVASC. PHARMACOL., vol.17, no.4, 1991 pages 587 - 592 W. NAYLER ET AL. '(-)[3H]amlodipine binding to rat cardiac membranes.'	
A	MOL. PHARMACOL., vol.43, no.2, 1993 pages 293 - 301 M. LAKITSCH ET AL. 'Heterogeneity of L-type calcium channel alpha-1 subunits: stereoselective discrimination of different populations by the novel 1,4-dihydropyridine B874-67'	

☐ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

11 November 1994

Date of mailing of the international search report

30. 11. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax (+ 31-70) 340-3016

Authorized officer

Klaver, T